umu.sePublications
Change search
ReferencesLink to record
Permanent link

Direct link
PBX3 is a putative biomarker of aggressive prostate cancer
Umeå University, Faculty of Medicine, Department of Medical Biosciences. Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Clin Pathol Cytol, Dept Lab Med, Huddinge, Sweden.
Show others and affiliations
2016 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 139, no 8, 1810-1820 p.Article in journal (Refereed) Published
Abstract [en]

There is a great need to identify new and better prognostic and predictive biomarkers to stratify prostate cancer patients for optimal treatment. The aims of this study were to characterize the expression profile of pre-B cell leukemia homeobox (PBX) transcription factors in prostate cancer with an emphasis on investigating whether PBX3 harbours any prognostic value. The expression profile of PBX3 and PBX1 in prostate tissue was determined by immunohistochemical and immunoblot analysis. Furthermore, the expression of PBX3 transcript variants was analyzed by RT-PCR, NanoString Technologies (R), and by analyzing RNA sequence data. The potential of PBX3 to predict prognosis, either at mRNA or protein level, was studied in four independent cohorts. PBX3 was mainly expressed in the nucleus of normal prostate basal cells, while it showed cytosolic expression in prostatic intraepithelial neoplasia and cancer cells. We detected four PBX3 transcript variants in prostate tissue. Competing risk regression analysis revealed that high PBX3 expression was associated with slower progression to castration resistant prostate cancer (sub-hazard ratio (SHR) 0.18, 95% CI: 0.081-0.42, p values < 0.001). PBX3 expression had a high predictive accuracy (area under the curve (AUC) = 0.82) when combined with Gleason score and age. Patients undergoing radical prostatectomy, with high levels of PBX3 mRNA, had improved prostate cancer specific survival compared to patients expressing low levels (SHR 0.21, 95% CI: 0.46-0.93, p values < 0.001, and AUC=0.75). Our findings strongly indicate that PBX3 has potential as a biomarker, both as part of a larger gene panel and as an immunohistochemical marker, for aggressive prostate cancer.

Place, publisher, year, edition, pages
2016. Vol. 139, no 8, 1810-1820 p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-126485DOI: 10.1002/ijc.30220ISI: 000383284500015PubMedID: 27273830OAI: oai:DiVA.org:umu-126485DiVA: diva2:1040519
Available from: 2016-10-27 Created: 2016-10-10 Last updated: 2016-10-27Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wang, Wanzhong
By organisation
Department of Medical Biosciences
In the same journal
International Journal of Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 3 hits
ReferencesLink to record
Permanent link

Direct link